# US 12,595,483 B2 · Treatment of tumors with miRNA targeting CDK4/CDK6

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,595,483 B2
- Document ID: US12595483B2
- Status: Granted
- Kind: B2
- Application number: 18/510,877
- Filed: 2023-11-16
- Published: 2024-06-13
- Granted: 2026-04-07
- Earliest claimed: 2017-02-26
- Assignees: Institute for Cancer Research Institute of Fox Chase Cancer Center
- Applicants: Institute For Cancer Research
- Inventors: Amriti R. Lulla; Wafik S. El-Deiry
- Web page: https://patentgrep.com/patent/US12595483B2

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.

## Claims

### Claim 1

A method for modulating expression of CDK4 and/or CDK6 in a tumor or cancer cell, the method comprising contacting a tumor or cancer cell selected from a colorectal cancer cell, a pancreatic cancer cell, and a melanoma cell with one or more oligonucleotides consisting of 15 to 40 linked nucleobases, or a salt thereof, wherein the one or more oligonucleotides comprises a nucleobase sequence that is at least 95% identical to a nucleobase sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, and wherein said contacting reduces the expression of CDK4 and/or CDK6 in the cell.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the one or more oligonucleotides is a modified oligonucleotide.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the one or more oligonucleotides is present in a pharmaceutical composition.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the oligonucleotide comprises a nucleobase sequence that is at least 95% identical to the nucleobase sequence of SEQ ID NO: 1.